



Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG

| | |
|------------------|-----------------------------|
| Last Trade: | 77.58 |
| Trade Time: | 12:48 PM ET Jun 18, 2018 |
| Change: | -0.50 (0.643%) |
| Day Range | 76.92 - 77.75 |
| 52-Week Range | 74.13 - 147.17 |
| Volume | 3,257,163 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID[®], VIDAZA[®], THALOMID[®], POMALYST[®]/IMNOVID[®], ABRAXANE[®], OTEZLA[®], ISTODAX[®] and IDHIFA[®]. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jun 3, 2018*
[Celgene Announces Updated Safety and Efficacy Data from the TRANSCEND Trial of liso-cel \(JCAR017\) in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma at ASCO](#)
- Jun 3, 2018*
[Results of Phase III RELEVANCE Study Comparing REVLIMID plus Rituximab \(R²\) Versus Rituximab Plus Chemotherapy in Patients with Previously Untreated Follicular Lymphoma to be Presented at ASCO 2018](#)
- Jun 1, 2018*
[Updated Results of Ongoing Multicenter Phase I Study of bb2121 anti-BCMA CAR T Cell Therapy Continue to Demonstrate Deep and Durable Responses in Patients with Late-Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting](#)
- Jun 1, 2018*
[Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVD Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma](#)

May 31, 2018
[Celgene Corporation Announces Hiring of David V. Elkins as Executive Vice President, Chief Financial Officer and Appointment of](#)

Financials [\[View all \]](#)

- Feb 7, 2018*
[Annual Report \(10-K\)](#)
- Apr 30, 2018*
[Proxy Statement \(DEF 14A\)](#)
- May 4, 2018*
[Quarterly Report \(10-Q\)](#)
- Oct 26, 2017*
[Quarterly Report \(10-Q\)](#)
- Jul 27, 2017*
[Quarterly Report \(10-Q\)](#)

Peter N. Kellogg to Executive Vice President,
Chief Corporate Strategy Officer